Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
the bull case· 4
16
disclosed supplier and customer ties reported in SEC filings
sec filingsedgar329
managers reporting a position in thirteen f filings
13fJun 30 '26+22.46%
change in shares held by the ten largest reporting managers last quarter
13fJun 30 '264
of the funds on file reporting a position in MIRM
n-portas of Jun 30 '26the bear case· 3
7 of 23
of the largest reporting managers cut their stake in the latest quarter
13fJun 30 '263 of 8
recent reports where the move came in under the options implied range
earnings historyimplied vs realized1.16%
of State Street SPDR S and P Biotech ETF assets as largest fund weight
n-portJun 30 '26Sides and captions by the model; every figure is ours. Built Sep 16 '26 for the Nov 4 '26 report. Not a forecast, not advice.
Of the 6 companies Mirum Pharmaceuticals, Inc. moves with most closely, none share its SEC classification.
Measured against 499 trading days of our own closes. Co-movement, not cause.
SIC 2834, Pharmaceutical Preparations, from each company's own filings. Largest first.
tall tick = annual report · 1 on record
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company's lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of Alagille syndrome and biliary atresia disease. It also develops Volixibat drug for treatment of intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Mirum Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Foster City, California.
Mirum Pharmaceuticals, Inc.
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
Nasdaq · Pharmaceutical Preparations
High 99.50 at 7:15 am ET, low 91.03 at 4:00 pm ET.
MIRM (Mirum Pharmaceuticals, Inc.) has 14 disclosed suppliers and 2 disclosed customers, strongest disclosure first.
Suppliers:
Customers:
Select a tie for its filing sentence; select again to open the company. Nearer the centre, the more the filings disclose. Extended: satellites hang off single companies, not bundled sectors.
327 managers report a position worth $8.4B between them, and 42 of them hold 80% of it.